The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease
- PMID: 15837551
- DOI: 10.1016/j.amjhyper.2004.11.040
The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease
Abstract
The current understanding of the interrelationships among hemodynamic, hormonal, and metabolic factors in the pathophysiology of renal disease remains incomplete. In the kidney, the renin-angiotensin system (RAS) plays an important role in all three of these physiologic pathways. There is no doubt that hypertension and diabetes are major risk factors for the progression of renal disease and that interruption of the RAS is renoprotective. In particular, the balance of interactions between angiotensin II and nitric oxide is a key factor in determining whether injury or protection of target organs ensues. Experimental studies suggest a novel link between hemodynamic and metabolic factors that may cooperate to induce progressive glomerular injury in conditions characterized by glomerular hypertension. Emerging data from experimental and clinical studies may lead to improvements in therapeutic efforts to prevent or slow the progression of renal disease.
Similar articles
-
Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.Int J Clin Pract. 2003 Nov;57(9):801-22. Int J Clin Pract. 2003. PMID: 14686572 Review.
-
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019. Clin Ther. 2007. PMID: 18035185 Review.
-
The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.Postgrad Med. 2009 Jan;121(1):96-103. doi: 10.3810/pgm.2009.01.1958. Postgrad Med. 2009. PMID: 19179817
-
The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.Am J Med. 2004 Feb 15;116(4):263-72. doi: 10.1016/j.amjmed.2003.09.034. Am J Med. 2004. PMID: 14969655 Review.
-
The renin-angiotensin system and diabetic nephropathy.Semin Nephrol. 2007 Mar;27(2):144-52. doi: 10.1016/j.semnephrol.2007.01.009. Semin Nephrol. 2007. PMID: 17418683 Review.
Cited by
-
Renoprotection Provided by Additional Diuretic Treatment in Partially Nephrectomized Ren-2 Transgenic Rats Subjected to the Combined RAS and ETA Blockade.Front Physiol. 2019 Sep 18;10:1145. doi: 10.3389/fphys.2019.01145. eCollection 2019. Front Physiol. 2019. PMID: 31620007 Free PMC article.
-
Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2.Hypertension. 2012 Sep;60(3):730-40. doi: 10.1161/HYPERTENSIONAHA.112.198622. Epub 2012 Jul 9. Hypertension. 2012. PMID: 22777933 Free PMC article.
-
The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes.Pharmaceutics. 2023 Apr 27;15(5):1343. doi: 10.3390/pharmaceutics15051343. Pharmaceutics. 2023. PMID: 37242585 Free PMC article. Review.
-
Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis.Am J Hypertens. 2015 Dec;28(12):1418-26. doi: 10.1093/ajh/hpv054. Epub 2015 May 11. Am J Hypertens. 2015. PMID: 25968123 Free PMC article.
-
Urinary Angiotensinogen in Patients With Type 1 Diabetes With Microalbuminuria: Gender Differences and Effect of Intensive Insulin Therapy.Kidney Int Rep. 2022 Sep 20;7(12):2657-2667. doi: 10.1016/j.ekir.2022.09.010. eCollection 2022 Dec. Kidney Int Rep. 2022. PMID: 36506234 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical